Novel Splice Variants as Potential Treatments for Rheumatoid Arthritis
Author Information
Author(s): Jin Pei, Zhang Juan, Sumariwalla Percy F, Ni Irene, Jorgensen Brett, Crawford Damian, Phillips Suzanne, Feldmann Marc, Shepard H Michael, Paleolog Ewa M
Primary Institution: Receptor BioLogix, Inc.
Hypothesis
Can novel alternative splice variants derived from receptor tyrosine kinases provide therapeutic benefits in rheumatoid arthritis?
Conclusion
Unique alternative splice variants derived from receptors involved in angiogenesis can significantly reduce the severity of arthritis.
Supporting Evidence
- 60 novel human alternative splice variants were cloned from 21 genes.
- ASV derived from VEGF receptor type 1 and Tie1 significantly reduced arthritis severity.
- Reduction in clinical signs of arthritis was observed in vivo.
- ASV showed binding to their cognate ligands.
Takeaway
Scientists found new proteins that can help treat arthritis by reducing swelling and pain in joints.
Methodology
The study involved cloning and characterizing 60 novel splice variants from 21 receptor genes and testing their effects in a mouse model of arthritis.
Potential Biases
Potential conflicts of interest due to authors' affiliations with a biotechnology company.
Limitations
The study primarily focused on a limited number of splice variants and their effects in a specific animal model.
Participant Demographics
Mice used in the study were DBA/1-Ola/Hsd, a common model for arthritis research.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website